Previous Next


№1' 2015


International Medical Journal, Vol. 21., Iss. 1, 2015, P. 58−62.


Maksim Yevgenevich Chernenko, Vovk V. I.

Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine
V. N. Karazin Kharkiv National University, Ukraine

Investigation of multiple sclerosis by modern neurology was started relatively recently, in the second half of the nineteenth century. This is a disease with marked clinical variability, unpredictable prognosis, unknown etiology and poorly understood pathogenesis. MS manifests by disorders of motor function, sensitive sphincter, intellectual mnestic disturbances, disorders of the organ of vision, autonomic dysfunction. MS is very common in young able−bodied persons who become disabled rapidly, making it a socio−economic problem. The prevalence of MS in Ukraine is 30 per 100 thousand, and an avalanche growth of MS with polymorphism of clinical manifestations complicating epidemiological and diagnostic investigations has been observed. In spite of the described difficulties, the literature data show that treatment of multiple sclerosis have been developed and implemented, although much remains unclear. The approach to evaluating the effectiveness of current treatment for MS is described. However, at present there are no clinical criteria that would allow predicting whether a particular drug is effective in each patient. None of the described drugs is sufficient to control the pathological process. Optimization of the schemes for diagnosis and treatment of MS, development of adequate, economically justified treatment algorithms at different stages of the disease are an important medical and economic task at present.

Key words: multiple sclerosis, pathogenetic therapy, literature review.

Go on Top